Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.12
Views: 3338
Rating:

Prof Yossef Yarden - Weizmann Institute of Science, Israel.

Promising new data on drug combinations to treat metastatic melanoma are presented at a press conference from the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

 

“These studies exemplify an important landmark of some tumours, which has emerged from recent laboratory research: the presence of specific mutations, such as the BRAF mutation in metastatic melanoma which exposes an Achilles' heel--MEK in this case,” said Prof Yossef Yarden from the Weizmann Institute of Science, Israel.

 

ecancerNews Coverage from ESMO 2012

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation